GLPwatch
Novel finding of pulmonary embolism following tirzepatide (Manjaro) use in a young adult without risk factors of venous thromboembolic events.
BMJ Case Rep · 2025
Last updated 2026-05-28A woman in her early 40s developed a pulmonary embolism after taking tirzepatide for 20 days, despite having no known risk factors for blood clots. Her symptoms included chest pain and shortness of breath, and a scan confirmed a blockage in her right lung artery. The case is the first reported possible link between tirzepatide and pulmonary embolism, but more research is needed to understand any connection.
AI summary of the abstract below.
| Journal | BMJ Case Rep, 2025 |
|---|---|
| Citations | 0 |
| Molecules | tirzepatide |
Abstract
A woman in her early 40s presented with pleuritic chest pain and shortness of breath, which had progressively worsened over 20 days following initiation of tirzepatide (Manjaro). Her D-dimer level was elevated at 1340 ng/mL, prompting a CT pulmonary angiogram that confirmed right main pulmonary artery pulmonary embolism (PE). The patient had no identifiable provoked or unprovoked risk factors for venous thromboembolisms (VTEs). To our knowledge, this is the first reported case of PE that might be associated with the use of tirzepatide worldwide. The relationship between tirzepatide and VTEs events remains unclear. This case highlights the need for further research to explore the incidence and underlying mechanisms of VTEs in patients receiving tirzepatide.
Verbatim abstract via PubMed 40669882 ↗
Related research
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
- Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.